<DOC>
	<DOCNO>NCT00529113</DOCNO>
	<brief_summary>This study assess safety efficacy RTA 402 combination gemcitabine patient unresectable pancreatic cancer .</brief_summary>
	<brief_title>Study With Gemcitabine RTA 402 Patients With Unresectable Pancreatic Cancer</brief_title>
	<detailed_description>Phase I conduct determine MTD RTA 402 ( administer orally Days 1-21 Days 1-28 28-day cycle ) combination gemcitabine ( 1000 m/m2 ) . Gemcitabine administer intravenous infusion Days 1 , 8 , 15 28-day cycle . The phase II portion study randomize , double-blinded . Phase II utilize RTA 402 MTD determine Phase I ; Arm 1 consist gemcitabine + RTA 402 . RTA 402 capsule administer orally Days 1-21 28-day cycle ( Days 1-28 appropriate , base phase I result ) ; gemcitabine ( 1000 mg/m2 ) administer intravenous infusion Days 1 , 8 , 15 28-day cycle Arm . Arm 2 consist gemcitabine + placebo , placebo capsule take orally Days 1-21 28-day cycle ( Days 1-28 appropriate , base phase I result ) . Both treatment arm 4-weeks length .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Phase I patient treatment naïve pancreatic cancer ; however , Phase I patient 1 prior regimen consist adjuvant chemoradiation adjuvant gemcitabine define within NCCN guideline may enrol . Phase II patient must metastatic disease ( Stage IV ) . Karnofsky performance status &gt; 70 % Adequate liver function . ( total bilirubin ≤ 1.5 mg/dL AST ( SGOT ) ALT ( SGPT ) &lt; 2.5 ULN ( ≤ 5 ULN Phase II patient liver metastasis ) , Serum Creatinine &lt; 1.5 ULN Adequate bone marrow function document follow laboratory test result within 14 day start therapy . platelet ≥100,000/mm3 , absolute neutrophil count ( ANC ) ≥1500/mm3 , hemoglobin ≥9.0 g/dL , white blood cell ( WBC ) count ≥3000 /mm3 Practice effective contraception entire study period . Life expectancy 3 month . Able willing sign inform consent form . Willing able selfadminister orally document dos RTA 402 ingest . Prior treatment current malignancy outside adjuvant set Phase I Inability swallow tablet capsule Active brain metastasis primary central nervous system ( CNS ) malignancy . ( Patients previously treat brain metastasis may include . ) Active second malignancy Ten percent great weight loss 6 week study entry . Pregnant breast feed Clinically significant illness could compromise participation study , include , limited : Uncontrolled diabetes ; Active uncontrolled infection ; Acute chronic liver disease ; Confirmed diagnosis Human immunodeficiency virus ( HIV ) infection ; Uncontrolled hypertension , symptomatic congestive heart failure , unstable angina pectoris , myocardial infarction within past 6 month , uncontrolled cardiac arrhythmia . Psychiatric illness would limit compliance study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>pancreatic cancer</keyword>
	<keyword>gemcitabine</keyword>
</DOC>